Coherus Oncology (CHRS) Free Cash Flow (2013 - 2026)

Coherus Oncology has reported Free Cash Flow for 14 years, with the latest figure at -$57.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 89.51% year-over-year to -$57.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304.5 million (up 750.87% YoY) and the FY2025 annual result came in at $331.8 million, up 59.99% from the prior year.
• Free Cash Flow eased to -$57.9 million in Q1 2026 per CHRS's latest filing, from -$28.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $436.8 million in Q2 2025 and troughed at -$100.0 million in Q4 2022.
• A 5-year average of $3.7 million and a median of -$39.0 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow slumped 8343.95% in 2022, then jumped 355.63% in 2024.
• Over 5 years, Free Cash Flow stood at -$100.0 million in 2022, then surged by 87.03% to -$13.0 million in 2023, then surged by 320.55% to $28.6 million in 2024, then slumped by 198.2% to -$28.1 million in 2025, then plunged by 106.06% to -$57.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$57.9 million, -$28.1 million, and -$46.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.